• Please log in or register to access this feature.

Original Article

You have full text access to this OnlineOpen article

Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis

  1. Michael R McClung1,*,
  2. Steven Boonen2,
  3. Ove Törring3,
  4. Christian Roux4,
  5. René Rizzoli5,
  6. Henry G Bone6,
  7. Claude-Laurent Benhamou7,
  8. Willem F Lems8,
  9. Salvatore Minisola9,
  10. Johan Halse10,
  11. Hans C Hoeck11,
  12. Richard Eastell12,
  13. Andrea Wang13,
  14. Suresh Siddhanti13,
  15. Steven R Cummings14

Article first published online: 22 DEC 2011

DOI: 10.1002/jbmr.536

Issue

Journal of Bone and Mineral Research

Journal of Bone and Mineral Research

Volume 27, Issue 1, pages 211–218, January 2012

Additional Information

How to Cite

McClung, M. R., Boonen, S., Törring, O., Roux, C., Rizzoli, R., Bone, H. G., Benhamou, C.-L., Lems, W. F., Minisola, S., Halse, J., Hoeck, H. C., Eastell, R., Wang, A., Siddhanti, S. and Cummings, S. R. (2012), Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis. J Bone Miner Res, 27: 211–218. doi: 10.1002/jbmr.536

Author Information

  1. 1

    Oregon Osteoporosis Center, Portland, OR, USA

  2. 2

    Division of Geriatric Medicine, Leuven University, Leuven, Belgium

  3. 3

    Karolinska Institutet Sodersjukhuset, Stockholm, Sweden

  4. 4

    Department of Rheumatology, Cochin Hospital, Paris Descartes University, Paris, France

  5. 5

    University Hospital, Geneva, Switzerland

  6. 6

    Michigan Bone and Mineral Clinic, Detroit, MI, USA

  7. 7

    INSERM U658, Orleans, France

  8. 8

    VU University Medical Center, Amsterdam, The Netherlands

  9. 9

    Sapienza, Università di Roma, Rome, Italy

  10. 10

    Osteoporoseklinikken, Oslo, Norway

  11. 11

    CCBR, Aalborg, Denmark

  12. 12

    National Institute for Health Research, Bone Biomedical Research Unit, University of Sheffield, Sheffield, United Kingdom

  13. 13

    Amgen Inc., Thousand Oaks, CA, USA

  14. 14

    San Francisco Coordinating Center, California Pacific Medical Center Research Institute and UCSF, San Francisco, CA, USA

*Oregon Osteoporosis Center, 5050 Northeast Hoyt, Suite 626, Portland, OR 97213, USA.

Publication History

  1. Issue published online: 22 DEC 2011
  2. Article first published online: 22 DEC 2011
  3. Accepted manuscript online: 4 OCT 2011 10:00AM EST
  4. Manuscript Accepted: 23 SEP 2011
  5. Manuscript Revised: 15 SEP 2011
  6. Manuscript Received: 19 JAN 2011

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (103K)

References

  • 1
    Bone HG, Bolognese MA, Yuen CK, Kendler DL, Wang H, Liu Y, San Martin J. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab. 2008; 93: 2149–57.
  • 2
    McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH, Lain D, Kivitz AJ, Holloway DL, Zhang C, Peterson MC, Bekker PJ. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006; 354: 821–31.
  • 3
    Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009; 361: 756–65.
  • 4
    Ensrud KE, Black DM, Palermo L, Bauer DC, Barrett-Connor E, Quandt SA, Thompson DE, Karpf DB. Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial. Arch Intern Med. 1997; 157: 2617–24.
  • 5
    Roux C, Reginster JY, Fechtenbaum J, Kolta S, Sawicki A, Tulassay Z, Luisetto G, Padrino JM, Doyle D, Prince R, Fardellone P, Sorensen OH, Meunier PJ. Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors. J Bone Miner Res. 2006; 21: 536–42.
    Direct Link:
  • 6
    Watts NB, Josse RG, Hamdy RC, Hughes RA, Manhart MD, Barton I, Calligeros D, Felsenberg D. Risedronate prevents new vertebral fractures in postmenopausal women at high risk. J Clin Endocrinol Metab. 2003; 88: 542–9.
  • 7
    Eastell R, Black DM, Boonen S, Adami S, Felsenberg D, Lippuner K, Cummings SR, Delmas PD, Palermo L, Mesenbrink P, Cauley JA. Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density. J Clin Endocrinol Metab. 2009; 94: 3215–25.
  • 8
    Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998; 280: 2077–82.
  • 9
    Chesnut IC, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004; 19: 1241–9.
    Direct Link:
  • 10
    Silverman SL, Christiansen C, Genant HK, Vukicevic S, Zanchetta JR, de Villiers TJ, Constantine GD, Chines AA. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res. 2008; 23: 1923–34.
    Direct Link:
  • 11
    Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C, Devogelaer JP, Curiel MD, Sawicki A, Goemaere S, Sorensen OH, Felsenberg D, Meunier PJ. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab. 2005; 90: 2816–22.
  • 12
    Boonen S, McClung MR, Eastell R, El-Hajj Fuleihan G, Barton IP, Delmas P. Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old. J Am Geriatr Soc. 2004; 52: 1832–9.
    Direct Link:
  • 13
    McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med. 2001; 344: 333–40.
  • 14
    Genant HK, Wu CY, van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res. 1993; 8: 1137–48.
    Direct Link:
  • 15
    Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16: 31–41.
  • 16
    Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine—reporting of subgroup analyses in clinical trials. N Engl J Med. 2007; 357: 2189–94.
  • 17
    Gail M, Simon R. Testing for qualitative interactions between treatment effects and patients subsets. Biometrics. 1985; 41: 361–72.
  • 18
    Genaro PS, Pereira GA, Pinheiro MM, Szejnfeld VL, Martini LA. Influence of body composition on bone mass in postmenopausal osteoporotic women. Arch Gerontol Geriatr. 2010; 51: 295–8.
  • 19
    Guglielmi G, van Kuijk C, Li J, Meta MD, Scillitani A, Lang TF. Influence of anthropometric parameters and bone size on bone mineral density using volumetric quantitative computed tomography and dual X-ray absorptiometry at the hip. Acta Radiol. 2006; 47: 574–80.
  • 20
    Judd HL, Davidson BJ, Frumar AM, Shamonki IM, Lagasse LD, Ballon SC. Serum androgens and estrogens in postmenopausal women with and without endometrial cancer. Am J Obstet Gynecol. 1980; 136: 859–71.
  • 21
    Judd HL, Lucas WE, Yen SS. Serum 17 beta-estradiol and estrone levels in postmenopausal women with and without endometrial cancer. J Clin Endocrinol Metab. 1976; 43: 272–8.
  • 22
    Zebaze RM, Ghasem-Zadeh A, Bohte A, Iuliano-Burns S, Mirams M, Price RI, Mackie EJ, Seeman E. Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross-sectional study. Lancet. 2010; 375: 1729–36.
View Full Article (HTML) Get PDF (103K)